CureVentures

Milenko Cicmil, Ph.D.

Partner

Dr. Cicmil is a Partner on the Cure investment team and serves as an interim operating executive for Cure’s portfolio companies.

CureVentures
CureVentures

We are driven to discern the most impactful technologies amongst the many great
ones we encounter.

CureVentures

Dr. Cicmil (Milenko) has over 20 years of experience in drug discovery and development, leading multi-disciplinary scientific/project teams, portfolio strategy, and business development. His deep understanding of biology, especially in inflammation/autoimmunity and oncology matched with his drug development experience across small molecules, biologics and peptides enables him to find creative solutions for challenges faced by early-stage biotechnology startups. He spent much of his career in R&D positions of increasing responsibility within companies such as Ipsen, Fog Pharma, Merck & Co., AstraZeneca, and GE Healthcare contributing to development of multiple drugs such as: Brilinta, Symbicort, and Keytruda.

Milenko is Co-founder of Tasca Therapeutics Corp., one of the Cure Ventures portfolio companies where he currently serves as the CEO and Board member. Most recently Milenko was Vice President and Head of Global External Innovation at Ipsen, responsible for developing and leading effort generating a high-value pipeline. Prior to joining Ipsen, Milenko was Vice President, Biology at Fog Pharma, where he was responsible for scientific, strategic, and operational leadership of the Biology Department as well as contributing efforts towards the company’s financing. During his career at Merck & Co., in addition to his R&D role Milenko also served as a Director at Merck’s Innovation Hub where he led search & evaluation efforts for in-licensing/partnership opportunities in Immuno-Oncology, Immunology and Ophthalmology. Milenko’s early R&D career at AstraZeneca spanned a variety of roles including managing teams of scientists and projects within immunology and inflammation therapy areas delivering over 20 clinical development candidate drugs.

Milenko is currently a Visiting Research Fellow at University of Reading, UK where he completed a Ph.D. in Molecular Pharmacology. Milenko received BSc in Molecular Biology from Kings College, London, UK. Prior to joining the pharmaceutical industry, Milenko was a postdoctoral fellow at the Cancer Research UK.

Go back to our team Go Back to Our Team